Pozen poised for profits after Vimovo wins approval

Shares of Pozen shot up 21 percent on Friday after the FDA sanctioned its new combo therapy for arthritis. Vimovo, developed in partnership with AstraZeneca, contains the NSAID pain drug naproxen along with the main ingredient for Nexium. London-based Gbola Amusa estimates that the drug--intended for arthritis patients in danger of developing an ulcer--could reap $500 million in sales revenue in 2014. The approval opens a new chapter in the development story of the Chapel Hill, NC-based Pozen....